Allin Kristine H, Bojesen Stig E, Nordestgaard Børge G
Herlev Hospital, Klinisk Biokemisk Afdeling, Herlev, Denmark.
Ugeskr Laeger. 2009 Nov 23;171(48):3510-3.
10,408 individuals from the general Danish population who had CRP measured at baseline were followed for up to 16 years; 1,624 developed cancer and among these, 998 died during follow-up. Multifactorially adjusted hazard ratios for the highest versus the lowest quintile of CRP were 1.3 (95% confidence interval, 1.0-1.6) for cancer of any type, 2.1 (1.2-3.8) for lung cancer, 1.7 (0.8-3.2) for colorectal cancer, and 0.9 (0.5-1.7) for breast cancer. Multifactorially adjusted hazard ratios for early death in patients with cancer were 1.8 (1.2-2.7) for CRP > 3 versus < 1 mg/L.
对丹麦普通人群中10408名在基线时测量了C反应蛋白(CRP)的个体进行了长达16年的随访;其中1624人患癌症,在这些患者中,998人在随访期间死亡。多因素调整后的CRP最高五分位数与最低五分位数相比,任何类型癌症的风险比为1.3(95%置信区间,1.0 - 1.6),肺癌为2.1(1.2 - 3.8),结直肠癌为1.7(0.8 - 3.2),乳腺癌为0.9(0.5 - 1.7)。癌症患者中,CRP>3mg/L与<1mg/L相比,多因素调整后的早期死亡风险比为1.8(1.2 - 2.7)。